---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-238065"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:52:50.314554+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness

## Summary
- Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.
- Daniel receives $415,900 base salary, 40% target bonus, and 578,000-share stock option grant vesting over 4 years.
- Daniel brings 25+ years life-science finance; previously SVP Finance at Bruker Spatial Biology until 2025.
- He has managed $400M cash portfolio and executed ~$1B in equity/debt transactions, supporting Atossa's commercial launch of (Z)-endoxifen.

## SEC filing metadata
- accession: 0001193125-25-238065
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/0001193125-25-238065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/atos-20251014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-238065
- JSON: https://secwatch.observer/filing/0001193125-25-238065.json
- Plain text: https://secwatch.observer/filing/0001193125-25-238065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.